JP2010516660A - ヒト免疫不全ウイルスの検出方法 - Google Patents

ヒト免疫不全ウイルスの検出方法 Download PDF

Info

Publication number
JP2010516660A
JP2010516660A JP2009545963A JP2009545963A JP2010516660A JP 2010516660 A JP2010516660 A JP 2010516660A JP 2009545963 A JP2009545963 A JP 2009545963A JP 2009545963 A JP2009545963 A JP 2009545963A JP 2010516660 A JP2010516660 A JP 2010516660A
Authority
JP
Japan
Prior art keywords
seq
high affinity
antigen
binding
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009545963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516660A5 (enExample
Inventor
サクセラ，カッレ
Original Assignee
ネクスト バイオメド テクノロジーズ エヌビーティー オイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクスト バイオメド テクノロジーズ エヌビーティー オイ filed Critical ネクスト バイオメド テクノロジーズ エヌビーティー オイ
Publication of JP2010516660A publication Critical patent/JP2010516660A/ja
Publication of JP2010516660A5 publication Critical patent/JP2010516660A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009545963A 2007-01-17 2008-01-17 ヒト免疫不全ウイルスの検出方法 Pending JP2010516660A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88535207P 2007-01-17 2007-01-17
FI20075028A FI120376B (fi) 2007-01-17 2007-01-17 Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
PCT/FI2008/050012 WO2008087254A2 (en) 2007-01-17 2008-01-17 Method for detection of human immunodeficiency virus

Publications (2)

Publication Number Publication Date
JP2010516660A true JP2010516660A (ja) 2010-05-20
JP2010516660A5 JP2010516660A5 (enExample) 2011-03-24

Family

ID=37745720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545963A Pending JP2010516660A (ja) 2007-01-17 2008-01-17 ヒト免疫不全ウイルスの検出方法

Country Status (8)

Country Link
US (1) US20100048407A1 (enExample)
EP (1) EP2109772A4 (enExample)
JP (1) JP2010516660A (enExample)
CN (1) CN101646944A (enExample)
AU (1) AU2008206881A1 (enExample)
CA (1) CA2675122A1 (enExample)
FI (1) FI120376B (enExample)
WO (1) WO2008087254A2 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508381A (ja) * 2000-09-04 2004-03-18 ビオノー　イムノ　アクスイェ　セルスカプ Ｈｉｖペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法
JP2004536568A (ja) * 2000-12-06 2004-12-09 アボット・ラボラトリーズ ヒト免疫不全ウイルスに対するモノクローナル抗体およびその用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508381A (ja) * 2000-09-04 2004-03-18 ビオノー　イムノ　アクスイェ　セルスカプ Ｈｉｖペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法
JP2004536568A (ja) * 2000-12-06 2004-12-09 アボット・ラボラトリーズ ヒト免疫不全ウイルスに対するモノクローナル抗体およびその用途

Also Published As

Publication number Publication date
EP2109772A4 (en) 2010-09-29
FI20075028A0 (fi) 2007-01-17
WO2008087254A2 (en) 2008-07-24
WO2008087254A8 (en) 2009-07-30
CN101646944A (zh) 2010-02-10
EP2109772A1 (en) 2009-10-21
FI20075028L (fi) 2008-07-18
US20100048407A1 (en) 2010-02-25
FI120376B (fi) 2009-09-30
CA2675122A1 (en) 2008-07-24
AU2008206881A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
CN107022027B (zh) Hiv-1广谱中和抗体及其用途
Huang et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Wang et al. Facile discovery of a diverse panel of anti-Ebola virus antibodies by immune repertoire mining
CN104520318B (zh) 针对jc病毒的vp1蛋白的人单克隆抗体
AU2013344322A1 (en) Diagnostic, prognostic, therapeutic and screening protocols
Chen et al. Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1
TWI867224B (zh) 重組抗體或片段，以及其用途
CN117126269B (zh) 一种1型人博卡病毒型别特异性抗体及其应用
CN106939034A (zh) 用于鉴定受试者所感染的hev基因型的方法和试剂盒
JP2010516660A (ja) ヒト免疫不全ウイルスの検出方法
WO2017065261A1 (ja) ヒトパルボウイルスｂ１９抗原および抗体の同時検出方法及びキット
JP7414225B2 (ja) ＳＡＲＳ－ＣｏＶ－２結合ペプチド
US8735328B2 (en) Fusion polypeptide for detection of conserved combinatorial or composite epitopes in non-conserved proteins
CN112175912B (zh) 杂交瘤细胞株3g4 1d6、抗gii.4型诺如病毒p蛋白单克隆抗体和应用
Riaz et al. Characterization of glycosylation-specific systemic and mucosal igA antibody responses to escherichia coli mucinase yghJ (SslE)
TW202216758A (zh) 抗人類免疫缺陷病毒－１抗體、包含其的細胞、核酸、組合物及套組
Liu et al. Bispecific monoclonal antibodies against a viral and an enzyme: utilities in ultrasensitive virus ELISA and phage display technology
CN117126270B (zh) 一种2型人博卡病毒型别特异性抗体及其应用
CN119462912B (zh) 抗埃博拉病毒vp40蛋白的纳米抗体及在病毒检测中的应用
CN112159797B (zh) 杂交瘤细胞株3g7 1b10、抗gii.4型诺如病毒p蛋白单克隆抗体和应用
Sanders Filamentous Bacteriophage as a Functional Biomaterial for Biomarker-Based Diagnostics
Merchant et al. Protein-based tools for the detection and characterisation of Oropouche virus infection
Burciaga-Flores et al. A New Approach in DENV Diagnostic based on Linear Peptides Obtained by Phage Display
CN114437205A (zh) 抗冠状病毒抗体及其应用
WO2013021277A1 (en) Recombinant ant-bovine iga antibody and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110203

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110203

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110930